Search
for
Sort by
Research 601–630 of 1000+
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Non‐biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases
- Thymic stromal lymphopoietin controls hair growth
- Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
- The emerging role of cellular senescence in amyotrophic lateral sclerosis
- Chemical Composition and Biological Activities of Essential Oils of Curcuma Species
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases
- Analyzing the role of ACE2, AR, MX1 and TMPRSS2 genetic markers for COVID-19 severity
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Alopecia Areata: An Updated Review for 2023
- Palatogenesis and cutaneous repair: A two‐headed coin
- A novel PLEC nonsense homozygous mutation (c.7159G > T; p.Glu2387*) causes epidermolysis bullosa simplex with muscular dystrophy and diffuse alopecia: a case report
- Ptosis in childhood
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Alopecia secondary to severe discoid lupus responding to anifrolumab
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Unusual acute lupus hemophagocytic syndrome – a test of diagnostic criteria: a case report
- The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis